Variant report

Variant	nsv894739
Chromosome Location	chr10:1643368-1669110
allele	n/a
Outlinks	Ensembl UCSC

Chromatin state
Related regulatory elements
Target genes
Other information

No.	Distal block	Cell Line	Cell type
1	chr10:1643971..1645583-chr10:1650285..1653262,2	K562	blood:
2	chr10:1637263..1639781-chr10:1644116..1647024,2	K562	blood:
3	chr10:1636416..1638763-chr10:1644116..1645883,2	K562	blood:
4	chr10:1643971..1645583-chr10:1650285..1653262,2	K562	blood:
5	chr10:1669032..1671336-chr10:1672737..1675449,2	MCF-7	breast:

Extended variants
information (count: 1370 )
Associated
traits (count: 56 )

Variant overlapped rSNPs/rCNVs (count:1370 , 50 per page) page: 1 2 3 4 5 6 7 ... 28

No.	Variant name	Chromosome position	Chromatin state	Related regulatory elements	Target genes	Extended variants	Associated traits
1	rs7898120	chr10:1643368-1643369	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	LD-proxies of rSNP Overlapped rCNV	n/a
2	rs376559442	chr10:1643388-1643389	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
3	rs2813401	chr10:1643393-1643394	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
4	rs552472634	chr10:1643401-1643402	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
5	rs369583313	chr10:1643405-1643406	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
6	rs562806708	chr10:1643415-1643416	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
7	rs369519564	chr10:1643438-1643439	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
8	rs183569705	chr10:1643462-1643463	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
9	rs116693073	chr10:1643467-1643468	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
10	rs143783366	chr10:1643477-1643478	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
11	rs568524505	chr10:1643493-1643494	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
12	rs34420802	chr10:1643520-1643521	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	LD-proxies of rSNP Overlapped rCNV	n/a
13	rs569259386	chr10:1643529-1643530	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
14	rs148164559	chr10:1643530-1643531	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
15	rs4293060	chr10:1643560-1643561	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	LD-proxies of rSNP Overlapped rCNV	n/a
16	rs576367135	chr10:1643599-1643600	Weak transcription Active TSS Enhancers Flanking Active TSS Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
17	rs574019921	chr10:1643600-1643601	Weak transcription Active TSS Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
18	rs112097406	chr10:1643612-1643613	Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
19	rs11250658	chr10:1643672-1643673	Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	LD-proxies of rSNP Overlapped rCNV	n/a
20	rs554663381	chr10:1643677-1643678	Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
21	rs145926951	chr10:1643681-1643682	Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
22	rs35407795	chr10:1643702-1643703	Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
23	rs190537975	chr10:1643703-1643704	Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
24	rs138534929	chr10:1643707-1643708	Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
25	rs573381272	chr10:1643746-1643747	Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
26	rs141604113	chr10:1643773-1643774	Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
27	rs75634439	chr10:1643816-1643817	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
28	rs531877074	chr10:1643842-1643843	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
29	rs541847548	chr10:1643845-1643846	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
30	rs571448453	chr10:1643856-1643857	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
31	rs561508949	chr10:1643870-1643871	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
32	rs150738886	chr10:1643884-1643885	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
33	rs568008528	chr10:1643913-1643914	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
34	rs113886930	chr10:1643934-1643935	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
35	rs547198732	chr10:1643940-1643941	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
36	rs570530414	chr10:1643946-1643947	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
37	rs182377043	chr10:1643951-1643952	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
38	rs74108945	chr10:1643952-1643953	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
39	rs151135394	chr10:1643973-1643974	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
40	rs570014922	chr10:1643978-1643979	Weak transcription Enhancers Bivalent Enhancer Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
41	rs139110534	chr10:1644014-1644015	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
42	rs554984742	chr10:1644016-1644017	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
43	rs568342544	chr10:1644017-1644018	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
44	rs113306169	chr10:1644081-1644082	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
45	rs76560162	chr10:1644082-1644083	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
46	rs553980923	chr10:1644126-1644127	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
47	rs576876221	chr10:1644145-1644146	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
48	rs546031203	chr10:1644175-1644176	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
49	rs5782586	chr10:1644193-1644194	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a
50	rs397747246	chr10:1644194-1644195	Weak transcription Enhancers Bivalent Enhancer	n/a	n/a	Overlapped CNVs	n/a

Variant related diseases (count:56)

Disease	PMID	Source
Myelofibrosis	22110671	CNVD
Breast cancer	20409316	CNVD
Gastric adenocarcinoma	19115996	CNVD
Pilocytic astrocytoma	18622384	CNVD
Pilomyxoid astrocytoma	18622384	CNVD
Breast cancer	17133270	CNVD
T-cell acute lymphoblastic leukemia	18185524	CNVD
Cancer	21129771	CNVD
Sudden cardiac death	19188705	CNVD
Digeorge syndrome	22283845	CNVD
Colorectal cancer	20709793	CNVD
Wilms tumour	19047088	CNVD
Hepatocellular carcinoma	16750200	CNVD
Acute myeloid leukemia	16864856	CNVD
Cancer	21183584	CNVD
Barakat syndrome	22470819	CNVD
Melanoma	18172304	CNVD
Ovarian cancer	21720365	CNVD
Autism	18414403	CNVD
Malignant melanoma	18718029	CNVD
Breast cancer	22032731	CNVD
Medulloblastoma	16783165	CNVD
Endometrioid adenocarcinoma	16974079	CNVD
Breast cancer	17603634	CNVD
Endometrial cancer	22040021	CNVD
Glioblastoma multiforme	21080181	CNVD
Breast cancer	21264507	CNVD
Esophageal squamous carcinoma	21637470	CNVD
Phyllodes tumor	17334353	CNVD
Acute lymphoblastic leukemia	17690704	CNVD
Pancreatic endocrine tumor	17639061	CNVD
Gastric cancer	17908304	CNVD
Chordoma	21602918	CNVD
Ewing''s sarcoma	21437220	CNVD
Medulloblastoma	21979893	CNVD
Pleomorphic xanthoastrocytoma	20730472	CNVD
small cell lung cancer	20016488	CNVD
Lung cancer	18438408	CNVD
Thoracic aortic aneurysm	21092924	CNVD
Melanoma	17363583	CNVD
low-grade B-cell lymphoma tumor	18367492	CNVD
Ewing''s sarcoma	17952124	CNVD
Oral cancer	21386901	CNVD
Breast cancer	21785460	CNVD
T-cell prolymphocytic leukemia	19278963	CNVD
Acute lymphoblastic leukemia	20435627	CNVD
Breast cancer	21509527	CNVD
Prostate cancer	18632612	CNVD
Hodgkin''s lymphoma	17606441	CNVD
Breast cancer	21858162	CNVD
Breast cancer	21364760	CNVD
Acute lymphoblastic leukemia	20724749	CNVD
Autism	22495311	CNVD
Autism	22543975	CNVD
Breast cancer	22522925	CNVD
Pancreatic cancer	17952125	CNVD

Chromatin state (count:222 , 50 per page) page: 1 2 3 4 5

No.	Chromosome Location	Chromatin state	Cell line	Tissue
1	chr10:1634600-1648200	Weak transcription	iPS DF 19.11 Cell Line	embryonic stem cell
2	chr10:1637600-1643800	Weak transcription	Fetal Brain Male	brain
3	chr10:1639800-1643600	Weak transcription	Fetal Brain Female	brain
4	chr10:1642400-1644000	Enhancers	Dnd41	blood
5	chr10:1643000-1643400	Active TSS	Foreskin Keratinocyte Primary Cells skin03	Skin
6	chr10:1643000-1643400	Enhancers	Brain Substantia Nigra	brain
7	chr10:1643000-1643600	Enhancers	Breast variant Human Mammary Epithelial Cells (vHMEC)	Breast
8	chr10:1643000-1645000	Bivalent Enhancer	Fetal Lung	lung
9	chr10:1643200-1643600	Active TSS	Breast Myoepithelial Primary Cells	Breast
10	chr10:1643200-1643800	Flanking Active TSS	Foreskin Keratinocyte Primary Cells skin02	Skin
11	chr10:1643200-1644000	Flanking Active TSS	NHEK	skin
12	chr10:1643200-1644200	Enhancers	Fetal Stomach	stomach
13	chr10:1643200-1645200	Weak transcription	Esophagus	oesophagus
14	chr10:1643400-1643600	Flanking Active TSS	Foreskin Keratinocyte Primary Cells skin03	Skin
15	chr10:1643400-1643800	Enhancers	GM12878-XiMat	blood
16	chr10:1643400-1643800	Enhancers	HMEC	breast
17	chr10:1643400-1644000	Bivalent Enhancer	Fetal Muscle Trunk	muscle
18	chr10:1643400-1644600	Enhancers	Fetal Thymus	thymus
19	chr10:1643600-1643800	Flanking Active TSS	Breast Myoepithelial Primary Cells	Breast
20	chr10:1643600-1644000	Enhancers	Fetal Brain Female	brain
21	chr10:1643600-1644200	Enhancers	Foreskin Keratinocyte Primary Cells skin03	Skin
22	chr10:1643800-1644000	Enhancers	Fetal Brain Male	brain
23	chr10:1643800-1644600	Enhancers	Breast Myoepithelial Primary Cells	Breast
24	chr10:1643800-1644600	Enhancers	Foreskin Keratinocyte Primary Cells skin02	Skin
25	chr10:1644000-1644200	Enhancers	NHEK	skin
26	chr10:1644000-1644800	Weak transcription	Fetal Brain Male	brain
27	chr10:1644200-1644400	Bivalent Enhancer	Fetal Stomach	stomach
28	chr10:1644200-1644800	Weak transcription	H9 Cell Line	embryonic stem cell
29	chr10:1644600-1648600	Weak transcription	Fetal Thymus	thymus
30	chr10:1644800-1645000	Genic enhancers	H9 Cell Line	embryonic stem cell
31	chr10:1644800-1645000	Active TSS	Fetal Brain Male	brain
32	chr10:1644800-1645200	Bivalent/Poised TSS	Fetal Kidney	kidney
33	chr10:1644800-1645200	Active TSS	NHDF-Ad	bronchial
34	chr10:1645000-1645200	Bivalent Enhancer	Fetal Brain Male	brain
35	chr10:1645000-1645400	Bivalent/Poised TSS	Fetal Lung	lung
36	chr10:1645000-1648400	Weak transcription	H9 Cell Line	embryonic stem cell
37	chr10:1645200-1645400	Enhancers	Esophagus	oesophagus
38	chr10:1648200-1648400	Enhancers	HUES48 Cell Line	embryonic stem cell
39	chr10:1648200-1648600	Enhancers	iPS DF 19.11 Cell Line	embryonic stem cell
40	chr10:1648400-1648600	Enhancers	H1 Cell Line	embryonic stem cell
41	chr10:1648400-1648600	Enhancers	iPS-20b Cell Line	embryonic stem cell
42	chr10:1648400-1648800	Enhancers	H9 Cell Line	embryonic stem cell
43	chr10:1648600-1648800	Enhancers	iPS-18 Cell Line	embryonic stem cell
44	chr10:1648600-1649000	Enhancers	Fetal Thymus	thymus
45	chr10:1648600-1650400	Weak transcription	iPS DF 19.11 Cell Line	embryonic stem cell
46	chr10:1648800-1651000	Weak transcription	H9 Cell Line	embryonic stem cell
47	chr10:1649800-1651800	Enhancers	iPS DF 6.9 Cell Line	embryonic stem cell
48	chr10:1650200-1651000	Bivalent Enhancer	iPS-18 Cell Line	embryonic stem cell
49	chr10:1650200-1651000	Enhancers	iPS-20b Cell Line	embryonic stem cell
50	chr10:1650200-1651600	Enhancers	hESC Derived CD184+ Endoderm Cultured Cells	ES cell derived

The 2.0 version of rSNPBase

Variant report

Quick Search:

what's new

Quick links